Sec Form 3 Filing - Lawson Byron @ HTG MOLECULAR DIAGNOSTICS, INC - 2020-01-23

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lawson Byron 2. Issuer Name and Ticker or Trading Symbol HTG MOLECULAR DIAGNOSTICS, INC [ HTGM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP/Chief Commercial Officer (Last) (First) (Middle) C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP 3. Date of Earliest Transaction (MM/DD/YY) 01/23/2020 (Street) TUCSON, AZ85706 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 43,449 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 2.15 ( 1 ) 10/02/2022 Common Stock 931 D Stock Option (right to buy) $ 2.15 ( 1 ) 01/31/2023 Common Stock 206 D Stock Option (right to buy) $ 2.15 ( 1 ) 08/05/2023 Common Stock 1,862 D Stock Option (right to buy) $ 2.15 ( 1 ) 03/19/2024 Common Stock 5,261 D Stock Option (right to buy) $ 12.89 ( 1 ) 12/28/2024 Common Stock 1,862 D Stock Option (right to buy) $ 5.08 ( 1 ) 11/24/2025 Common Stock 10,000 D Stock Option (right to buy) $ 2.83 ( 2 ) 05/25/2026 Common Stock 5,000 D Stock Option (right to buy) $ 1.75 ( 1 ) 01/31/2027 Common Stock 10,000 D Stock Option (right to buy) $ 3.46 ( 3 ) 05/31/2027 Common Stock 5,000 D Stock Option (right to buy) $ 2.39 ( 1 ) 07/25/2027 Common Stock 7,500 D Stock Option (right to buy) $ 3.4 ( 4 ) 08/16/2028 Common Stock 30,000 D Stock Option (right to buy) $ 1.38 ( 5 ) 08/06/2029 Common Stock 65,000 D Stock Option (right to buy) $ 0.8 ( 5 ) 09/12/2029 Common Stock 35,000 D Stock Option (right to buy) $ 0.75 ( 6 ) 01/07/2030 Common Stock 70,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lawson Byron C/O HTG MOLECULAR DIAGNOSTICS, INC. 3430 E. GLOBAL LOOP TUCSON, AZ85706 SVP/Chief Commercial Officer Signatures /s/ Shaun D. McMeans, Attorney-in-Fact 02/03/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares subject to the stock option are fully vested. ( 2 )The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after May 25, 2016. ( 3 )The shares subject to the option will vest every three months in equal installments over four years beginning on August 31, 2017, such that the options is fully vested on May 31, 2021. ( 4 )The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after August 16, 2018. ( 5 )The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on September 30, 2019, such that the stock option is fully vested on August 31, 2021. ( 6 )The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on January 31, 2020, such that the stock option is fully vested on December 31, 2021.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.